Recent Security Class Actions

Neumora Therapeutics Inc. Common Stock (NASDAQ: NMRA)

35 Days left to seek lead plaintiff status.

Company Name:Neumora Therapeutics Inc. Common Stock
Stock Symbol:NASDAQ: NMRA
Class Period Start:09/15/2023
Class Period End (inclusive):02/06/2025
Filing Deadline:04/07/2025

The Complaint alleges that the Offering Documents issued in connection with Neumora's IPO contained false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn’s original Phase Two Trial inclusion criteria to include a patient population with moderate to severe MDD to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. When the true details entered the market, the lawsuit claims that investors suffered damages.

Neumora Therapeutics Inc. Common Stock (NASDAQ: NMRA) Claim Form

Name(Required)
Address
This field is for validation purposes and should be left unchanged.